Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

10.1182/blood-2013-12-546374

Saved in:

Bibliographic Details
Main Authors:	San-Miguel, J, Bladé, J, Shpilberg, O, Grosicki, S, Maloisel, F, Min, C.-K, Zarzuela, M.P, Robak, T, Prasad, S.V.S.S, Goh, Y.T, Laubach, J, Spencer, A, Mateos, M.-V, Palumbo, A, Puchalski, T, Reddy, M, Uhlar, C, Qin, X, Van De Velde, H, Xie, H, Orlowski, R.Z
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	American Society of Hematology 2020
Subjects:	antivirus agent bisphosphonic acid derivative bortezomib immunoglobulin A interleukin 6 melphalan prednisone siltuximab add on therapy adult aged anemia article bleeding bone disease bronchopneumonia chromosome 17p drug efficacy drug fatality drug response drug safety gastrointestinal disease herpes zoster human hypokalemia incidence infection leukocytoclastic vasculitis maintenance therapy major clinical study multicenter study multiple myeloma neuralgia neutropenia overall survival peripheral neuropathy phase 2 clinical trial pneumonia priority journal progression free survival radius fracture respiratory failure sensory neuropathy septic shock suicide thrombocytopenia very elderly Aged Aged, 80 and over Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols Boronic Acids Chromosome Deletion Chromosomes, Human, Pair 17 Disease-Free Survival Female Follow-Up Studies Humans Immunoglobulin A Interleukin-6 Male Melphalan Middle Aged Multiple Myeloma Prednisone Pyrazines Survival Rate
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/183894
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-183894
record_format	dspace
spelling	sg-nus-scholar.10635-1838942020-12-04T10:02:31Z Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma San-Miguel, J Bladé, J Shpilberg, O Grosicki, S Maloisel, F Min, C.-K Zarzuela, M.P Robak, T Prasad, S.V.S.S Goh, Y.T Laubach, J Spencer, A Mateos, M.-V Palumbo, A Puchalski, T Reddy, M Uhlar, C Qin, X Van De Velde, H Xie, H Orlowski, R.Z DUKE-NUS MEDICAL SCHOOL antivirus agent bisphosphonic acid derivative bortezomib immunoglobulin A interleukin 6 melphalan prednisone siltuximab add on therapy adult aged anemia article bleeding bone disease bronchopneumonia chromosome 17p drug efficacy drug fatality drug response drug safety gastrointestinal disease herpes zoster human hypokalemia incidence infection leukocytoclastic vasculitis maintenance therapy major clinical study multicenter study multiple myeloma neuralgia neutropenia overall survival peripheral neuropathy phase 2 clinical trial pneumonia priority journal progression free survival radius fracture respiratory failure sensory neuropathy septic shock suicide thrombocytopenia very elderly Aged Aged, 80 and over Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols Boronic Acids Chromosome Deletion Chromosomes, Human, Pair 17 Disease-Free Survival Female Follow-Up Studies Humans Immunoglobulin A Interleukin-6 Male Melphalan Middle Aged Multiple Myeloma Prednisone Pyrazines Survival Rate 10.1182/blood-2013-12-546374 Blood 123 26 4136-4142 2020-11-23T08:57:00Z 2020-11-23T08:57:00Z 2014 Article San-Miguel, J, Bladé, J, Shpilberg, O, Grosicki, S, Maloisel, F, Min, C.-K, Zarzuela, M.P, Robak, T, Prasad, S.V.S.S, Goh, Y.T, Laubach, J, Spencer, A, Mateos, M.-V, Palumbo, A, Puchalski, T, Reddy, M, Uhlar, C, Qin, X, Van De Velde, H, Xie, H, Orlowski, R.Z (2014). Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123 (26) : 4136-4142. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2013-12-546374 0006-4971 https://scholarbank.nus.edu.sg/handle/10635/183894 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ American Society of Hematology Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	antivirus agent bisphosphonic acid derivative bortezomib immunoglobulin A interleukin 6 melphalan prednisone siltuximab add on therapy adult aged anemia article bleeding bone disease bronchopneumonia chromosome 17p drug efficacy drug fatality drug response drug safety gastrointestinal disease herpes zoster human hypokalemia incidence infection leukocytoclastic vasculitis maintenance therapy major clinical study multicenter study multiple myeloma neuralgia neutropenia overall survival peripheral neuropathy phase 2 clinical trial pneumonia priority journal progression free survival radius fracture respiratory failure sensory neuropathy septic shock suicide thrombocytopenia very elderly Aged Aged, 80 and over Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols Boronic Acids Chromosome Deletion Chromosomes, Human, Pair 17 Disease-Free Survival Female Follow-Up Studies Humans Immunoglobulin A Interleukin-6 Male Melphalan Middle Aged Multiple Myeloma Prednisone Pyrazines Survival Rate
spellingShingle	antivirus agent bisphosphonic acid derivative bortezomib immunoglobulin A interleukin 6 melphalan prednisone siltuximab add on therapy adult aged anemia article bleeding bone disease bronchopneumonia chromosome 17p drug efficacy drug fatality drug response drug safety gastrointestinal disease herpes zoster human hypokalemia incidence infection leukocytoclastic vasculitis maintenance therapy major clinical study multicenter study multiple myeloma neuralgia neutropenia overall survival peripheral neuropathy phase 2 clinical trial pneumonia priority journal progression free survival radius fracture respiratory failure sensory neuropathy septic shock suicide thrombocytopenia very elderly Aged Aged, 80 and over Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols Boronic Acids Chromosome Deletion Chromosomes, Human, Pair 17 Disease-Free Survival Female Follow-Up Studies Humans Immunoglobulin A Interleukin-6 Male Melphalan Middle Aged Multiple Myeloma Prednisone Pyrazines Survival Rate San-Miguel, J Bladé, J Shpilberg, O Grosicki, S Maloisel, F Min, C.-K Zarzuela, M.P Robak, T Prasad, S.V.S.S Goh, Y.T Laubach, J Spencer, A Mateos, M.-V Palumbo, A Puchalski, T Reddy, M Uhlar, C Qin, X Van De Velde, H Xie, H Orlowski, R.Z Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
description	10.1182/blood-2013-12-546374
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL San-Miguel, J Bladé, J Shpilberg, O Grosicki, S Maloisel, F Min, C.-K Zarzuela, M.P Robak, T Prasad, S.V.S.S Goh, Y.T Laubach, J Spencer, A Mateos, M.-V Palumbo, A Puchalski, T Reddy, M Uhlar, C Qin, X Van De Velde, H Xie, H Orlowski, R.Z
format	Article
author	San-Miguel, J Bladé, J Shpilberg, O Grosicki, S Maloisel, F Min, C.-K Zarzuela, M.P Robak, T Prasad, S.V.S.S Goh, Y.T Laubach, J Spencer, A Mateos, M.-V Palumbo, A Puchalski, T Reddy, M Uhlar, C Qin, X Van De Velde, H Xie, H Orlowski, R.Z
author_sort	San-Miguel, J
title	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
title_short	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
title_full	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
title_fullStr	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
title_full_unstemmed	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
title_sort	phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-il-6) in multiple myeloma
publisher	American Society of Hematology
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/183894
_version_	1686109315162701824

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

Similar Items